Standard mRNA Had a Good Run. Then Came This.

Phase 3 data shows Arcturus' sa-mRNA vaccine produces more durable, functionally superior antibody responses than conventional mRNA

10 Apr 2026

A sequence of three mRNA shots was, for most of the world, the sum total of pandemic-era vaccination. That it worked was not in question. Whether it worked as well as it could have is now being revisited.

A study published on March 30th in npj Vaccines, led by researchers at Harvard T.H. Chan School of Public Health alongside Arcturus Therapeutics, compared ARCT-154, a self-amplifying mRNA (sa-mRNA) vaccine developed by the San Diego biotech, against BioNTech's conventional mRNA product as a fourth booster dose. The results favour the newer platform in ways that go beyond simple antibody counts.

The researchers used systems serology, a technique that maps the full functional behaviour of antibodies rather than merely tallying them. ARCT-154 produced a more sustained, activating immune profile. Notably, elevated antibody activity was recorded against BA.5, a variant that had drifted considerably from the original vaccine target. This suggests the platform builds a broader adaptive response, not merely a stronger one against known strains.

The biological mechanism is straightforward. Conventional mRNA degrades within days of injection. Self-amplifying mRNA encodes its own replication machinery, extending antigen production over weeks. The immune system, in effect, trains for longer, and trains differently. The qualitative gap in antibody function appears to be a consequence of that extended window rather than any novel immunological trick.

Sa-mRNA's earlier selling point was efficiency: lower doses to achieve comparable results. This Phase 3 data adds a harder claim. At the functional level, the platform may not merely match conventional mRNA but outperform it. That distinction matters as researchers push sa-mRNA into cancer vaccines, rare disease treatments, and infectious disease programmes well beyond COVID-19.

Whether regulators and manufacturers will accelerate the shift remains to be seen. Platform transitions carry logistical and commercial inertia. Yet the question the industry once debated, whether sa-mRNA could match established mRNA technology, has now been reframed. The more pressing question is how quickly the field catches up with the answer.